SCHEMBL9609322

SCHEMBL9609322

N#Cc1ccc(C#N)c(-c2nc(-c3ccccc3O)nc(-c3ccccc3O)n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
AR P10275 3/20 0.43
PGR P06401 2/20 0.43
EGFR P00533 3/20 0.43
ADORA3 P0DMS8 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA2B P29275 1/20 0.42
ADORA1 P30542 1/20 0.42
KMT2A Q03164 1/20 0.41
KDM4C Q9H3R0 1/20 0.41
ESR2 Q92731 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CHUK O15111 1/20 0.39
CYP11B1 P15538 1/20 0.39
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9608443 0.81 ADORA3 (0.51) MAPK1SMN1; SMN2ARPGREGFR
SCHEMBL9608399 0.80 MAPK1 (0.40) MAPK1SMN1; SMN2ARPGRADORA3
SCHEMBL9608389 0.80 ADORA2A (0.57) MAPK1SMN1; SMN2ADORA3ALOX15TSHR
SCHEMBL15909991 0.80 ADORA2A (0.57) MAPK1SMN1; SMN2ADORA3ALOX15TSHR
SCHEMBL9609312 0.80 TSHR (0.53) MAPK1SMN1; SMN2ARPGRADORA3
SCHEMBL9608483 0.79 CLK4 (0.53) MAPK1SMN1; SMN2ADORA3ALOX15TSHR
SCHEMBL15909994 0.78 TSHR (0.49) MAPK1SMN1; SMN2ARPGREGFR
SCHEMBL15909989 0.78 ADORA3 (0.55) MAPK1SMN1; SMN2ADORA3ALOX15TSHR
SCHEMBL12250864 0.78 NPC1 (0.45) SMN1; SMN2ARPGRTSHRADORA2A
SCHEMBL15909992 0.78 CLK4 (0.51) MAPK1SMN1; SMN2ADORA3ALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2460799-B1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORP (JP) 2018-05-02 EP disclosed
US-20160200933-A1 RESIN COMPOSITION, PROTECTIVE FILM FOR POLARIZING PLATE, POLARIZING PLATE, AND DISPLAY FUJIFILM CORPORATION (JP) 2016-07-14 US disclosed
US-8957140-B2 Triazine derivative, ultraviolet absorber, and resin composition FUJIFILM CORPORATION (JP) 2015-02-17 US disclosed
US-8748520-B2 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORPORATION (JP) 2014-06-10 US disclosed
US-8623990-B2 Polyester resin composition FUJIFILM CORPORATION (JP) 2014-01-07 US disclosed
EP-2301995-B1 Polycarbonate resin composition containing triazine compound and molded article using the same FUJIFILM CORP (JP) 2013-11-06 EP disclosed
US-20120301696-A1 POLYESTER RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-11-29 US disclosed
EP-2460799-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM Corporation (JP) 2012-06-06 EP disclosed
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION FUJIFILM CORPORATION (JP) 2012-05-31 US disclosed
US-20110077331-A1 POLYCARBONATE RESIN COMPOSITION CONTAINING TRIAZINE COMPOUND AND MOLDED ARTICLE USING THE SAME FUJIFILM CORPORATION (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136098-A1 NEW TRIAZINE DERIVATIVE, ULTRAVIOLET ABSORBER, AND RESIN COMPOSITION C1R, RPSA, H1-2 MAPK1 4321/4885SMN1; SMN2 3721/4885AR 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.